Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes
| Autor: | François Mach, Xiaodong Gu, Steven E. Nissen, Thomas F. Lüscher, Yoon-Mi Chung, Zeneng Wang, Lorenz Räber, Benjamin J Hazen, Bruce S. Levison, Christian M. Matter, Alex G Hurd, Xinmin S. Li, Slayman Obeid, Alan Pratt, David Nanchen, Stanley L. Hazen, Yuping Wu, Lin Li, W.H. Wilson Tang |
|---|---|
| Přispěvatelé: | University of Zurich, Hazen, Stanley L |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Fast Track Clinical Research 610 Medicine & health 030204 cardiovascular system & hematology Chest pain 2705 Cardiology and Cardiovascular Medicine 11459 Center for Molecular Cardiology Methylamines 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Humans Medicine Prospective Studies 030212 general & internal medicine Myocardial infarction Acute Coronary Syndrome Aged Troponin T business.industry Lysine Hazard ratio Odds ratio Middle Aged Prognosis medicine.disease Confidence interval 3. Good health Cardiovascular Diseases Cohort 10209 Clinic for Cardiology Cardiology Female medicine.symptom Cardiology and Cardiovascular Medicine business Biomarkers Mace |
| Zdroj: | Eur Heart J |
| ISSN: | 1522-9645 0195-668X |
| DOI: | 10.1093/eurheartj/ehz259 |
| Popis: | Aims Trimethyllysine (TML) serves as a nutrient precursor of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) and is associated with incident cardiovascular (CV) events in stable subjects. We examined the relationship between plasma TML levels and incident CV events in patients presenting with acute coronary syndromes (ACS). Methods and results Plasma levels of TML were quantified in two independent cohorts using mass spectrometry, and its relationship with CV events was investigated. In a Cleveland Cohort (N = 530), comprised of patients presenting to the emergency department with chest pain and suspected ACS, TML was associated with major adverse cardiac events (MACE, myocardial infarction, stroke, need for revascularization, or all-cause mortality) over both 30 days [3rd tertile (T3), adjusted odds ratio (OR) 1.77, 95% confidence interval (CI) 1.04–3.01; P Conclusion Plasma TML levels, alone and together with TMAO, are associated with both near- and long-term CV events in patients with chest pain and ACS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|